Time-Of-Flight PET Map out Goals by Joel S
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
PET/CT Evaluation of Cardiac Sarcoidosis
PET/CT Evaluation of Cardiac Sarcoidosis John P. Bois, MDa,*, Daniele Muser, MDb,1, Panithaya Chareonthaitawee, MDa KEYWORDS Cardiac sarcoidosis Positron emission tomography Fluorine-18 deoxyglucose KEY POINTS Sarcoidosis can involve the heart at with resultant significant morbidity and mortality. PET/CT is the most accurate method by which to diagnose cardiac sarcoidosis. Patient preparation prior to the PET/CT cardiac sarcoid study is critical to ensure diagnostic images are obtained. PET/CT detection of both active inflammation and scar has diagnostic, prognostic, and therapeutic importance. Ongoing areas of research include the use of PET to quantify the extent of myocardial inflammation and the discrepancies in myocardial blood flow in the cardiac sarcoidosis population. INTRODUCTION experiencing spontaneous remission and the remaining one-third developing either a stable or The increasing implementation of advanced car- progressive course.3 diovascular imaging in the form of cardiac PET/ The rate of cardiac involvement by sarcoidosis, CT has had a significant impact on the manage- otherwise termed CS, is variable and ranges ment of cardiac sarcoidosis (CS), one that con- from 20% to 75%.4,5 Furthermore, CS accounts tinues to evolve. Sarcoidosis is characterized for one-fourth of sarcoid-related mortality in the histologically by the presence of noncaseating United States and upward of 85% of death attrib- granulomas, with a predilection for the pulmonary uted to sarcoidosis in the Japanese population.4,6 system but with the ability to involve nearly every The high rate of involvement of the cardiovascular organ. Although the development of sarcoidosis system by sarcoidosis coupled with the potential is believed the sequelae of an exaggerated im- lethal outcomes has rendered accurate and timely mune or inflammatory response to an inciting in- diagnosis of this disease entity as imperative to fectious or environmental trigger, the specific patient care. -
A Comparison of Imaging Modalities for the Diagnosis of Osteomyelitis
A comparison of imaging modalities for the diagnosis of osteomyelitis Brandon J. Smith1, Grant S. Buchanan2, Franklin D. Shuler2 Author Affiliations: 1. Joan C Edwards School of Medicine, Marshall University, Huntington, West Virginia 2. Marshall University The authors have no financial disclosures to declare and no conflicts of interest to report. Corresponding Author: Brandon J. Smith Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia Email: [email protected] Abstract Osteomyelitis is an increasingly common pathology that often poses a diagnostic challenge to clinicians. Accurate and timely diagnosis is critical to preventing complications that can result in the loss of life or limb. In addition to history, physical exam, and laboratory studies, diagnostic imaging plays an essential role in the diagnostic process. This narrative review article discusses various imaging modalities employed to diagnose osteomyelitis: plain films, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, bone scintigraphy, and positron emission tomography (PET). Articles were obtained from PubMed and screened for relevance to the topic of diagnostic imaging for osteomyelitis. The authors conclude that plain films are an appropriate first step, as they may reveal osteolytic changes and can help rule out alternative pathology. MRI is often the most appropriate second study, as it is highly sensitive and can detect bone marrow changes within days of an infection. Other studies such as CT, ultrasound, and bone scintigraphy may be useful in patients who cannot undergo MRI. CT is useful for identifying necrotic bone in chronic infections. Ultrasound may be useful in children or those with sickle-cell disease. Bone scintigraphy is particularly useful for vertebral osteomyelitis. -
Isotope Production Potential at Sandia National Laboratories: Product, Waste, Packaging, and Transportation*
Isotope Production Potential at Sandia National Laboratories: Product, Waste, Packaging, and Transportation* A. J. Trennel Transportation Systems Department *- *-, o / /"-~~> Sandia National Laboratories** ' J Albuquerque, NM 87185 O Q T » Abstract The U.S. Congress directed the U.S. Department of Energy to establish a domestic source of molybdenum-99, an essential isotope used in nuclear medicine and radiopharmacology. An Environmental Impact Statement for production of 99Mo at one of four candidate sites is being prepared. As one of the candidate sites, Sandia National Laboratories is developing the Isotope Production Project. Using federally approved processes and procedures now owned by the U.S. Department of Energy, and existing facilities that would be modified to meet the production requirements, the Sandia National Laboratories' Isotope Project would manufacture up to 30 percent of the U.S. market, with the capacity to meet 100 percent of the domestic need if necessary. This paper provides a brief overview of the facility, equipment, and processes required to produce isotopes. Packaging and transportation issues affecting both product and waste are addressed, and the storage and disposal of the four low-level radioactive waste types generated by the production program are considered. Recommendations for future development are provided. This work was performed at Sandia National Laboratories, Albuquerque, New Mexico, for the U.S. Department of Energy under Contract DE-AC04-94AL85000. A U.S. Department of Energy facility. DISTRPJTO OF THIS DOCUMENT IS UNLIMITED #t/f W A8 1 fcll PROJECT NEED AND BACKGROUND Nuclear medicine is an expanding segment of today's medical and pharmaceutical communities. Specific radioactive isotopes are vital, with molybdenum-99 (99Mo) being the most important medical isotope. -
Consensus Nomenclature Rules for Radiopharmaceutical Chemistry – Setting the Record Straight
ÔØ ÅÒÙ×Ö ÔØ Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight Heinz H. Coenen, Antony D. Gee, Michael Adam, Gunnar Antoni, Cathy S. Cutler, Yasuhisa Fujibayashi, Jae Min Jeong, Robert H. Mach, Thomas L. Mindt, Victor W. Pike, Albert D. Windhorst PII: S0969-8051(17)30318-9 DOI: doi: 10.1016/j.nucmedbio.2017.09.004 Reference: NMB 7967 To appear in: Nuclear Medicine and Biology Received date: 21 September 2017 Accepted date: 22 September 2017 Please cite this article as: Coenen Heinz H., Gee Antony D., Adam Michael, Antoni Gunnar, Cutler Cathy S., Fujibayashi Yasuhisa, Jeong Jae Min, Mach Robert H., Mindt Thomas L., Pike Victor W., Windhorst Albert D., Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight, Nuclear Medicine and Biology (2017), doi: 10.1016/j.nucmedbio.2017.09.004 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight Recommended guidelines, assembled by an international and inter- society working group after extensive consultation with peers in the wider field of nuclear chemistry and radiopharmaceutical sciences. Heinz H. Coenen1*, Antony D. Gee2*, Michael Adam3, Gunnar Antoni4, Cathy S. -
Myocardial Perfusion Imaging with PET
SPECIAL CONTRIBUTION Myocardial Perfusion Imaging with PET Markus Schwaiger Nuklearmedizinische Klinik und Poliklini/çDer Technischen Universitdt Munchen, Klini/wm Rechts der Isar, Munich, Germany SPEC!' (5). PET spatial resolution is superior to that of AlthoughSPECThas become an acceptedimagingtechnique SPECT, resulting in superior image quality and less partial formyocardialperfusionstudies,thereare severaladvantages volume effect (5). Most PET images are processed with a to evaluatingcoronaryarterydisease (CAD)withPET.CADis a spatial resolution of about 6—10mm, as compared with complex, dynamic disease and quantitativemeasurements of 10—15mm for SPECF image reconstruction. myocardialbloodflowby PET can improvethe fUnCtiOnalchar The majoradvantageof PET is its ability to correct for acterizationof CAD.The majoradvantage of PET over SPECT attenuation.Traditionalmyocardialperfusionimagingwith is @rtsabilityto provideattenuation-correctedimages, whichde single-photon radiotracers such as 201'flposes significant creases incidenceof attenuation artifactsand increases spea challenges in avoiding or identifying and correcting for flcfty.Myocardialpertusion imagingwithPET can also provide moreaccurateinformationon localizationofdisease, as wellas attenuation artifacts, particularly those that involve the quantitativeassessment, inabsolutevalues, ofmyocardialblood inferior wall in male patients and the anterior wall in female flow.The measurement ofregionalflowreserve allowsforphys patients (6,7). iologiccharacterizationof stenosis severity, -
Atrium Health Delineation of Privileges Specialty of Radiology
ATRIUM HEALTH DELINEATION OF PRIVILEGES SPECIALTY OF RADIOLOGY Print Name YES NO** I have participated in direct patient care in the hospital setting within the past two (2) years. **If the answer is No, please do not complete this form. Contact the Medical Staff Office at (704) 355-2147 for additional instructions regarding the required proctoring process. Initial appointment Reappointment Updated DOP Request for Clinical Privileges To be eligible for core privileges in Radiology, the applicant must meet the following qualifications: If the applicant is not currently certified in Radiology by the American Board of Medical Specialties (ABMS) or the American Osteopathic Association (AOA) the applicant must: 1. Provide documentation of successful completion of an ACGME or AOA accredited Radiology training program, within the past five (5) years; AND 2. Provide documentation of the performance and interpretation of at least five-thousand (5,000) imaging tests in the past two (2) years. Applicants have the burden of producing information deemed adequate by the hospital for proper evaluation of current competence, and other qualifications and for resolving any doubts; OR If the applicant is currently certified in Radiology by the American Board of Medical Specialties (ABMS) or the American Osteopathic Association (AOA), the applicant must: 1. Provide documentation of general pediatric certification from the American Board of Medical Specialties or the American Osteopathic Association (AOA); AND 2. Provide documentation of the performance and interpretation of at least five-thousand (5,000) imaging tests in the past two (2) years. Applicants have the burden of producing information deemed adequate by the hospital for proper evaluation of current competence, and other qualifications and for resolving any doubts. -
Cardiac Radiology)
CAE002-b F-18 FDG PET/CT and MRI In the Diagnosis and Management of Cardiac Sarcoidosis Education Exhibits Location: CA Community, Learning Center Participants Richard Anthony R. Coulden MD (Presenter): Nothing to Disclose Emer Sonnex : Nothing to Disclose Hefin Jones FRCR : Nothing to Disclose Indrajeet Das MBBCh, MRCP : Nothing to Disclose Jonathan Thomas Abele MD : Nothing to Disclose TEACHING POINTS In patients with established non-cardiac sarcoidosis, both FDG PET/CT and cardiac MRI can be used to diagnose cardiac involvement. We will learn how and why: 1. FDG PET/CT identifies active disease and can be used in both diagnosis and management. Serial PET allows assessment of response to immunosuppressive treatment. 2. Cardiac MRI identifies myocardial edema and scar. It has proven value in diagnosis but its role in monitoring disease in response to treatment is unclear. 3. Cardiac MRI provides additional value in assessment of ventricular volumes and function and maybe a helpful surrogate in monitoring treatment response. 4. FDG PET/CT and MRI are complementary techniques. TABLE OF CONTENTS/OUTLINE 1. Criteria for clinical diagnosis of cardiac sarcoidosis (Japanese Ministry of Health and Welfare) 2. How to use FDG PET/CT for inflammatory cardiac imaging 3. How to use cardiac MRI for infiltrative cardiomyopathies 4. Relative roles of Cardiac MRI and FDG PET/CT in: a. the imaging diagnosis of cardiac sarcoidosis b. follow-up of disease activity and response to immunosuppressive treatment. CAE004-b Dynamic Myocardial Perfusion Imaging by 3rd Generation Dual-Source CT Education Exhibits Location: CA Community, Learning Center Participants Marisa Marjolein Lubbers MD (Presenter): Nothing to Disclose Adriaan Coenen MD : Nothing to Disclose Akira Kurata : Nothing to Disclose Marcel L. -
Progress in Radiopharmacology
INIS-mf—11544 Proceedings of the Vth International Symposium on Radiopharmacology PROGRESS IN RADIOPHARMACOLOGY EDITORS A. E. A. MITTA R. A. CARO C. O. CANELLAS 986 BUENOS AIRES - REPUBLICA ARGENTINA 1987 & ,f<? 000 Y'{ Proceedings of the Vth International Symposium on Radiopharmacology PROGRESS IN RADIOPHARMACOLOGY EDITORS A. E. A. MITTA R. A. CARO C. O. CANELLAS 986 BUENOS AIRES - REPUBLICA ARGENTINA 1987 Proceedings of the Vth International Symposium on Radiopharmacology PROGRESS IN RADIOPHARMACOLOGY EDITORS A. E. A. MITTA Comision Nacional de Energia Atomica Buenos Aires, Republics Argentina R. A. CARO Facultad de Farmacia y Bioquimica Universidad de Buenos Aires, Republics Argentina C. O. CAIVIELLAS Comision Nacional de Energia Atomica Buenos Aires, Republica Argentina PREFACE This book contains most of the papers presented at the V International Symposium on Radiopharmacology held at Buenos Aires, Argentina, from the 29th to the 31st October, 1986. The papers were put into the same order as they were presented at the symposium. The V Simposium was sponsored by the Argentine Atomic Energy Commission, which allowed, among other things, the edition of this book. I want to acknowledge specially the cordial assistance of Profs.DlSiRicardo.A.Caro and Carlos. O.Canellas in the publication of the present book. PREFACE The Executive Committee of the V International Symposium on Radiopharmacology acknowledges deeply the participation of all those who presented their paper, discussed the results or simply assisted to the sympos ium. The proceedings we are publishing herewith are the result of the efforts of the authors who sent us the full papers, as well as the excellent work done by the Printing Department of the Argentine Atomic Energy Commission. -
Advertising (PDF)
CintiChemAreTheTechnetìumHeaviestYou'll99mGeneratorsFind- OnPurpose YourSafety isOurConcernjitt Technetium 99m Generators from And all ClntiChem Technetium 99m Cintichem, Inc. have 3.77 inches of lead Generators from Medi-Physics surrounding the column for maximum incorporate the following important radiation protection. The secondary advantages: shield adds 5/8" more lead to make our •A NEW STERILE NEEDLE is utilized for generators safer yet. And only MPI Gen each elution, reducing the chances of a erators offer depleted uranium shielding septic or pyrogenic situation occurring in higher calibrations, designed to max in routine clinical usage. imize radiation protection, convenience •See, 10cc AND 20cc EVACUATED and reduce costs. With 20 sizes and 2 ELUTION VIALS are available, allowing calibration days, we can meet virtually you to optimize the elution concentra every need. tion to meet your needs. Convenience is also designed INTO every •RIGID QUALITY CONTROL TESTING, MPI Generator. It is the only generator which includes an elution check on with rapid, easy horizontal elution via a each Generator, assures that it meets shielded elution port. The simple, one- our rigid internal specifications. The step elution reduces work time while assurance that 20 years experience in eliminating direct eye exposure during nuclear medicine brings. the elution process. Eluate sterility is •ACCESSIBLE CUSTOMER SERVICE assured by the 0.22 micron filter on the on toll free telephone numbers. Our terminal fluid line and an autoclaved service personnel have in depth back column. grounds in research, development, technical and clinical applications in nuclear medicine. We are concerned about your safety. That will be evident when you receive your first CintiChem generator from MPI. -
Evicore Cardiac Imaging Guidelines
CLINICAL GUIDELINES Cardiac Imaging Policy Version 1.0 Effective February 14, 2020 eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2019 eviCore healthcare. All rights reserved. Cardiac Imaging Guidelines V1.0 Cardiac Imaging Guidelines Abbreviations for Cardiac Imaging Guidelines 3 Glossary 4 CD-1: General Guidelines 5 CD-2: Echocardiography (ECHO) 15 CD-3: Nuclear Cardiac Imaging 26 CD-4: Cardiac CT, Coronary CTA, and CT for Coronary Calcium (CAC) 33 CD-5: Cardiac MRI 40 CD-6: Cardiac PET 45 CD-7: Diagnostic Heart Catheterization 49 CD-8: Pulmonary Artery and Vein Imaging 56 CD-9: Congestive Heart Failure 59 CD-10: Cardiac Trauma 62 CD-11: Adult Congenital Heart Disease 64 CD-12: Cancer Therapeutics-Related -
Myocardial Perfusion Imaging Versus CT Coronary Angiography: When to Use Which?
CONTINUING EDUCATION Myocardial Perfusion Imaging Versus CT Coronary Angiography: When to Use Which? Balaji Tamarappoo and Rory Hachamovitch Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the various types of noninvasive cardiac imaging tests and how the results of each are utilized; (2) recent advances in CT coronary angiography, PET myocardial perfusion imaging, and SPECT myocardial perfusion imaging of coronary artery disease; and (3) the clinical use of anatomic versus physiologic tests in symptomatic patients with known or suspected coronary artery disease. Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through June 2012. suspected coronary artery disease (CAD). The results of Both anatomy- and physiology-based approaches to patient these tests are used for patient risk stratification, evaluation management have advantages and limitations. Compared of myocardial ischemia as a cause of symptoms, and assess- with the latter, the former has a superior ability to exclude ment of ongoing disease management. Stress myocardial disease and does not miss high-risk coronary artery disease (CAD). -
Basics and Principles of Radiopharmaceuticals for PET/CT
European Journal of Radiology 73 (2010) 461–469 Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Review Basics and principles of radiopharmaceuticals for PET/CT W. Wadsak a, M. Mitterhauser a,b,∗ a Department of Nuclear Medicine, Medical University of Vienna, Austria b Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Austria article info abstract Article history: The presented review provides general background on PET radiopharmaceuticals for oncological appli- Received 1 December 2009 cations. Special emphasis is put on radiopharmacological, radiochemical and regulatory aspects. This Accepted 15 December 2009 review is not meant to give details on all different PET tracers in depth but to provide insights into the general principles coming along with their preparation and use. Keywords: The PET tracer plays a pivotal role because it provides the basis both for image quality and clinical Radiopharmaceutical interpretation. It is composed of the radionuclide (signaller) and the molecular vehicle which determines Tracer the (bio-)chemical properties (e.g. binding characteristics, metabolism, elimination rate). Radiopharmacology Radiochemistry © 2010 Published by Elsevier Ireland Ltd. This section is intended to provide general background on PET resulting in abnormal function it can probably be visualized long radiopharmaceuticals for oncological application. Special empha- before morphological manifestation. sis is put on radiopharmacological, radiochemical and regulatory Basically, there are three major disciplines that have to inter- aspects. This review is not meant to give details on all different PET act and collaborate closely to enable the successful application of tracers in depth but to provide insights into the general principles PET/CT in a clinical setting: medical physics, radiopharmaceuti- coming along with their preparation and use.